Page results
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the spine (backbone).
-
This information has been written for parents and carers whose child is having radiotherapy treatment to the whole lungs. The page explains the side effects your child may experience during and after treatment, and how best to cope with them.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the whole brain and spine. This treatment may also be referred to as whole central nervous system (CNS) or cranio-spinal radiotherapy.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the whole brain.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the abdomen and pelvis.
-
This page is for parents and carers whose child is having radiotherapy treatment to the chest, or mediastinum.
-
This page provides information about the Modified Exercise Test.
-
CAR T-cell therapy is a cutting-edge treatment for certain blood cancers, offering new hope to patients whose illness hasn’t responded to standard treatments. University College London Hospitals (UCLH) is proud to be one of Europe’s leading centres for this advanced care.
-
This page is about histiocytic disorders treated at the UCLH haematology department.
-
This page aims to provide information about the syndrome haemophagocytic lymphohistiocytosis (HLH).
File results
-
FOI/2019/524 UCLH Phase 5 contractors
-
FOI/2023/0331 - Sexual assaults in hospitals from 2020 to 2023
-
FOI/2019/516 TMS and SCS protocols, guidelines and treatment pathways
-
FOI/2019/514 Benchmarking tool
-
FOI/2019/484 Homless patients admitted to ED
-
FOI/2023/0292 - Spend on bank/ agency/ locum staff for junior doctor strike cover
-
FOI/2023/0340 - NHS charging of overseas visitors
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0338 - Individuals with a change to a gene called CACNA1C for 2021 and 2022
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology